Streetbeat News

ANEB

Anebulo Pharmaceuticals, Inc.

https://www.anebulo.com

Industry

Biotechnology

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

Open

1.55

Mkt cap

39M

Volume

1.8K

High

1.57

P/E Ratio

-5.07

52-wk high

3.30

Low

1.52

Div yield

N/A

52-wk low

1.46

In Thursday's intraday session, several healthcare stocks experienced significant movements. HOOKIPA Pharma (HOOK) saw a 73.2% increase, while HeartBeam (BEAT) rose by 54.23%. PetVivo Holdings (PETV), OneMedNet (ONMD), Anebulo Pharmaceuticals (ANEB), and MeiraGTx Holdings (MGTX) also saw upward movements ranging from 27.89% to 39.02%. On the downside, Clene (CLNN) dropped by 41.5%, Aclarion (ACON) by 28.06%, Panbela Therapeutics (PBLA) by 24.47%, Longeveron (LGVN) by 22.05%, Genetic Technologies (GENE) by 15.37%, and Know Labs (KNW) by 13.51% after their Q4 earnings report was released two days ago.

Portfolio Pulse from Benzinga Insights

December 21, 2023 | 5:32 pm

Anebulo Pharmaceuticals (NASDAQ:ANEB) reported Q1 EPS losses of $(0.10), surpassing the consensus estimate of $(0.12) by 16.67%. This represents a 9.09% improvement from the $(0.11) per share loss reported in the same quarter last year.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 9:59 pm

The article lists the stocks that gained and lost in Tuesday's mid-day session. Notable gainers include SciSparc Ltd., Assembly Biosciences, Inc., and Olink Holding AB, while notable losers include Evelo Biosciences, Inc., Monte Rosa Therapeutics, Inc., and Nuvve Holding Corp. The article also mentions that ServisFirst Bancshares shares are trading lower by 6% after the company reported third-quarter earnings.

Portfolio Pulse from Lisa Levin

October 17, 2023 | 5:42 pm

During Tuesday's intraday session, several healthcare stocks experienced significant movements. Nkarta, Assembly Biosciences, Olink Holding, Anebulo Pharmaceuticals, Moleculin Biotech, and OpGen saw their shares rise, while Evelo Biosciences, Monte Rosa Therapeutics, Celcuity, Tiziana Life Sciences, Better Therapeutics, and Nuvectis Pharma experienced a decline in their stock prices.

Portfolio Pulse from Benzinga Insights

October 17, 2023 | 5:31 pm

Anebulo Pharmaceuticals Inc has announced Richie Cunningham as its new Chief Executive Officer and a member of the company's Board of Directors.

Portfolio Pulse from Benzinga Newsdesk

October 06, 2023 | 8:07 pm

Benchmark analyst Robert Wasserman has reiterated a Speculative Buy on Anebulo Pharmaceuticals (NASDAQ:ANEB) and maintained an $8 price target.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 3:52 pm

Anebulo Pharmaceuticals has appointed Daniel George as the company's part-time CFO, Principal Financial Officer, and Principal Accounting Officer, effective from September 28, 2023. He replaces Sandra Gardiner.

Portfolio Pulse from Benzinga Newsdesk

September 29, 2023 | 11:23 am

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Anebulo Pharmaceuticals (NASDAQ:ANEB) and maintained a $6 price target.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 10:10 am

Maxim Group analyst Michael Okunewitch has initiated coverage on Anebulo Pharmaceuticals (NASDAQ:ANEB) with a Buy rating and a price target of $6.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 3:49 pm

Anebulo Pharmaceuticals reported Q4 losses of $(0.10) per share, beating the analyst consensus estimate of $(0.12) by 16.67 percent. This is unchanged from the same period last year.

Portfolio Pulse from Happy Mohamed

September 20, 2023 | 8:30 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.